These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21116002)

  • 1. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
    Eaddy M; Seal B; Tangirala M; Davies EH; O'Day K
    Am J Health Syst Pharm; 2010 Dec; 67(24):2110-4. PubMed ID: 21116002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
    Eaddy M; Seal B; Tangirala K; Davies EH; O'Day K
    Appl Health Econ Health Policy; 2012 Nov; 10(6):431-40. PubMed ID: 23013428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS; Thompson S; Tangirala K; Eaddy MT
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
    Holdsworth MT; Nguyen P
    Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 7. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
    Abousaud MI; Rush MC; Rockey M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome.
    Patel S; Le A; Gascon S
    Am J Health Syst Pharm; 2012 Jun; 69(12):1015-6. PubMed ID: 22644973
    [No Abstract]   [Full Text] [Related]  

  • 10. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasburicase in the prevention and treatment of tumour lysis syndrome.
    Mayne N; Keady S; Thacker M
    Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA; Herrera N; Rohatgi R
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
    Campara M; Shord SS; Haaf CM
    J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome].
    Tatay VS; Castilla JD; Ponce JM; Hurtado JM; Cantero E; Abril ML
    An Pediatr (Barc); 2010 Feb; 72(2):103-10. PubMed ID: 20022572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
    J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
    Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
    Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
    Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
    J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.